Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0001403
UniProt IDP15260
Primary gene name(s)IFNGR1
Synonym gene name(s)unknown
Protein nameInterferon gamma receptor 1
Protein functionAssociates with IFNGR2 to form a receptor for the cytokine interferon gamma, IFNG, PubMed:7615558, PubMed:2971451, PubMed:7617032, PubMed:10986460. Ligand binding stimulates activation of the JAK/STAT signaling pathway, PubMed:7673114. {ECO:0000269|PubMed:10986460, ECO:0000269|PubMed:2971451, ECO:0000269|PubMed:7615558, ECO:0000269|PubMed:7617032, ECO:0000269|PubMed:7673114}.
Subcellular locationCell membrane {ECO:0000269|PubMed:10811850};
Single-pass type I membrane protein {ECO:0000255}.
ECO codeClick here for more information.
Amino acid sequence
FASTA format: P15260
Gene Ontology
(Biological Process)
Complete annatation
interferon-gamma-mediated signaling pathway [GO:0060333];
regulation of interferon-gamma-mediated signaling pathway [GO:0060334];
response to virus [GO:0009615];
signal transduction [GO:0007165]
Gene Ontology
(Molecular Function)
Complete annatation
interferon-gamma receptor activity [GO:0004906];
interleukin-20 binding [GO:0042015]
Gene Ontology
(Cellular Component)
Complete annatation
integral component of plasma membrane [GO:0005887];
plasma membrane [GO:0005886]
Protein-protein interaction109681
Phylogenetic treeP15260
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
      unknown
Brass et al., Science, 2008
      unknown
Smith et al., J. Immunol, 2010
      unknown
Interferon-stimulated
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model


DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD3-1.229632478859090.0002258819504329380.000987095609430339
AZA vs. DISU0.1652718812682310.5143033742957670.938237240336917
AZA vs. IL7-0.01134404285427480.9531723892336450.999311006273513
AZA vs. SAHA0.1773650395382890.4689319235312550.804495567593122
DISU vs. CD31.38135199136480.0001876499097155370.000983188995151896
DISU vs. IL7-0.1855632626344820.4621363686911470.802985910329535
DISU vs. SAHA0.01351203132627770.9630942507114530.992637214624418
DMSO vs. AZA-0.03374679906441190.8414429910786391
DMSO vs. CD31.182101300326310.0002791033928003510.00111619129613413
DMSO vs. DISU-0.2014463989937820.409952285976230.870383340329923
DMSO vs. IL70.02981153577616070.8689860531898680.971237921925134
DMSO vs. SAHA0.2050806297357680.3861149970142740.733443297202183
HIV vs. Mock in Activation-0.3168929455990820.6119181990118440.999983755607037
HIV vs. Mock in Latency-0.105798583679830.5239054469847250.999834320637052
IL7 vs. CD31.2264523541510.0001754231152707450.0009514762923627
SAHA vs. CD31.381788277007010.0001369467105938330.000631707048867174
SAHA vs. IL70.1850127466932410.4493163696024480.687993040574393
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
unknown unknown

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock unknown unknown unknown
Infected vs. Bystander unknown unknown unknown
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change unknown
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
unknown unknown unknown unknown unknown unknown
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) TRUE
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
OK -0.0928121 0.586519
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
unknown unknown

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
unknown unknown unknown unknown unknown
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
unknown unknown unknown unknown unknown unknown unknown
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category
202727_s_at 1.39 No downregulated in CD8+ cells
211676_s_at 1.46 No downregulated in CD8+ cells

Protein Overview       top

Drug-protein Interaction       (annotations from DrugBank)      top

Drugbank ID Drug Name Drug Status Pharmacological Action Drug Action
DB00033 Interferon gamma-1b approved, investigational yes binder

Protein Secondary Structure       (annotations from PDB)      top

PDB Accession Method Resolution Chain Structure Preview
1FG9 X-ray 2.9Å C/D/E=18-262.
1FYH X-ray 2.0Å B/E=18-246.
1JRH X-ray 2.8Å I=18-125.

HIV-1 Interaction       (annotations from NCBI HIV-1 Interaction Database)      top

HIV Partner Interaction Type PubMed
Nef downregulates 25275127
Vpu downregulates 25275127
Vpu modulates 26172439

Metabolic/Signalling Pathway       (annotations from KEGG database)      top

Pathway Accession Number Description
hsa04060 Cytokine-cytokine receptor interaction - Homo sapiens (human)
hsa04066 HIF-1 signaling pathway - Homo sapiens (human)
hsa04380 Osteoclast differentiation - Homo sapiens (human)
hsa04630 Jak-STAT signaling pathway - Homo sapiens (human)
hsa04650 Natural killer cell mediated cytotoxicity - Homo sapiens (human)
hsa04658 Th1 and Th2 cell differentiation - Homo sapiens (human)
hsa04659 Th17 cell differentiation - Homo sapiens (human)
hsa05132 Salmonella infection - Homo sapiens (human)
hsa05140 Leishmaniasis - Homo sapiens (human)
hsa05142 Chagas disease (American trypanosomiasis) - Homo sapiens (human)
hsa05145 Toxoplasmosis - Homo sapiens (human)
hsa05152 Tuberculosis - Homo sapiens (human)
hsa05162 Measles - Homo sapiens (human)
hsa05164 Influenza A - Homo sapiens (human)
hsa05168 Herpes simplex infection - Homo sapiens (human)
hsa05321 Inflammatory bowel disease (IBD) - Homo sapiens (human)
Menu